---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-399378"
form_type: "8-K"
ticker: "EVMN"
cik: "0002044725"
company_name: "Evommune, Inc."
filed_at: "2026-09-23T20:05:30+00:00"
generated_at: "2026-09-23T20:06:43.033954+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Evommune to present Phase 2a EVO301 AD data at EADV 2026; Phase 2b planned mid-2027

## Summary
- Phase 2a EVO301 (IL-18 binding protein) atopic dermatitis data in late-breaker Oct 1 at EADV Vienna; presenter Dr. Mark G. Lebwohl.
- Topline results previously reported this year; Phase 2b dose-ranging study in moderate-to-severe AD expected to start mid-2027.
- EVO301 targets IL-18 upstream of Th2 axis, modulating Th1, Th2, Th17/22 and innate inflammatory pathways.
- CEO Luis Peña cites 29M patients in 7 major markets needing advanced AD therapy; IL-18 offers broad-spectrum potential.

## SEC filing metadata
- accession: 0001193125-26-399378
- form_type: 8-K
- ticker: EVMN
- cik: 0002044725
- company_name: Evommune, Inc.
- filed_at: 2026-09-23T20:05:30+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2044725/000119312526399378/0001193125-26-399378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2044725/000119312526399378/evmn-20260923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-399378
- JSON: https://secwatch.observer/filing/0001193125-26-399378.json
- Plain text: https://secwatch.observer/filing/0001193125-26-399378.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.